Effect of juglans regial on diabetes

Evaluating the effect of juglans regial extract on blood glucose and lipid profile in type II diabetic patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201106076720N1

Enrollment

Registered

2012-03-09

Start date

2010-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Diabetes. Condition 2: Disorder of lipoprotein metabolism. Non-insulin-dependent diabetes mellitus Disorder of lipoprotein metabolism, unspecified

Interventions

Intervention 1: Intervention: Juglans regial extrac powder 200 mg in capsule two times a day for three months. Intervention 2: Control: placebo 200 mg in capsule two times a day for three months.

Treatment - Drugs

Placebo

Intervention: Juglans regial extrac powder 200 mg in capsule two times a day for three months

Control: placebo 200 mg in capsule two times a day for three months

Eligibility

Sex/Gender

All

Age

40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between 40 to 60 years; confirmed type II diabetes at least for two years with fasting blood glucose 150-250 mg/dl; taking metformin or glibencalamid; having HbA1c 7.5-10%; All patients singed the written informed consent. Exclusion criteria: insulin therap; infectious diseases; severe kidney disease with Cr>270 umol/L; liver, heart or pulmonary disease; hypersensitivity to any drug; foot ulcer or gangrene; major depressive disorders; active cancer or previous cancer during the last 5 years; alcohol consumption; cigarette smoking; pregnancy and breast feeding.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Glycosylated hemoglobin. Timepoint: Baseline and after three months. Method of measurement: HPLC method.;TG - total cholesterole. Timepoint: Baseline and after three months. Method of measurement: Fasting blood Cholesterol and TG level in Baseline and after three months by enzymatic oxidase method.;Fasting blood glucose. Timepoint: Baseline and after three months. Method of measurement: Glucose oxidase method.	—

Measure

Time frame

Glycosylated hemoglobin. Timepoint: Baseline and after three months. Method of measurement: HPLC method.;TG - total cholesterole. Timepoint: Baseline and after three months. Method of measurement: Fasting blood Cholesterol and TG level in Baseline and after three months by enzymatic oxidase method.;Fasting blood glucose. Timepoint: Baseline and after three months. Method of measurement: Glucose oxidase method.

—

Secondary

Measure	Time frame
SGOT. Timepoint: Baseline and after three months. Method of measurement: SGOT level in fasting blood sample by DGKG enzymatic method.;SGPT. Timepoint: Baseline and after three months. Method of measurement: SGPT level in fasting blood sample by DGKG enzymatic method.;Creatinin. Timepoint: Baseline and after three months. Method of measurement: The fasting blood Creatinin level by JAPH enzymatic method.	—

Measure

Time frame

SGOT. Timepoint: Baseline and after three months. Method of measurement: SGOT level in fasting blood sample by DGKG enzymatic method.;SGPT. Timepoint: Baseline and after three months. Method of measurement: SGPT level in fasting blood sample by DGKG enzymatic method.;Creatinin. Timepoint: Baseline and after three months. Method of measurement: The fasting blood Creatinin level by JAPH enzymatic method.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLeila Jamshidi

Endocrinology & Metabolism Research Center

Leila_jamshidi4@yahoo.com

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026